CD14 and chronic kidney disease: In CKD patients, the proinflammatory intermediate CD14++CD16+ monocytes exhibit marked uptake of oxidized LDL with low cholesterol efflux capacity, high production of Interleukin (IL)-6, and IL-1β and tumor necrosis factor alpha (TNF-α), and appear to be linked to adverse cardiovascular outcomes [9,10].